Firefly Neuroscience, Inc.
AIFF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.05 | -0.00 | 0.06 |
| FCF Yield | -4.10% | -6.70% | -6.43% | -5.85% |
| EV / EBITDA | -14.18 | -16.90 | -2.31 | -8.23 |
| Quality | ||||
| ROIC | -27.42% | -13.46% | -39.83% | -1,077.12% |
| Gross Margin | 37.63% | 91.64% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.56 | 1.30 | 0.19 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.42% | -40.43% | 1,266,630.18% | 1,260,157.36% |
| Free Cash Flow Growth | 34.47% | 4.61% | -93.99% | 51.62% |
| Safety | ||||
| Net Debt / EBITDA | 1.80 | 3.34 | 0.75 | 0.44 |
| Interest Coverage | -265.60 | -108.93 | -16.13 | -104.12 |
| Efficiency | ||||
| Inventory Turnover | 3.03 | 0.19 | 0.00 | 0.00 |
| Cash Conversion Cycle | -470.45 | -4,869.10 | 209.30 | 205.47 |